# Gerhardt Attard

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/gerhardt-attard/

## Facts

| Field | Value |
| --- | --- |
| Citations | 35,790 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 87 |
| i10-index | 229 |
| Last Known Institution | University College Hospital |
| OpenAlex ID | https://openalex.org/A5000156180 |
| ORCID iD | 0000-0002-4811-7983 |
| Works | 572 |

## Researcher papers

Showing 12 of 13.

- [DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer](https://scholariq.org/papers/dna-repair-defects-and-olaparib-in-metastatic-prostate-cancer/)
- [Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial](https://scholariq.org/papers/addition-of-docetaxel-zoledronic-acid-or-both-to-first-line-long-term-hormone/)
- [Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy](https://scholariq.org/papers/abiraterone-for-prostate-cancer-not-previously-treated-with-hormone-therapy/)
- [Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial](https://scholariq.org/papers/radiotherapy-to-the-primary-tumour-for-newly-diagnosed-metastatic-prostate/)
- [Prostate cancer](https://scholariq.org/papers/prostate-cancer/)
- [Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven](https://scholariq.org/papers/phase-i-clinical-trial-of-a-selective-inhibitor-of-cyp17-abiraterone-acetate/)
- [ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group](https://scholariq.org/papers/esmo-recommendations-on-the-use-of-circulating-tumour-dna-assays-for-patients/)
- [The Lancet Commission on prostate cancer: planning for the surge in cases](https://scholariq.org/papers/the-lancet-commission-on-prostate-cancer-planning-for-the-surge-in-cases/)
- [Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-the-report-of-the-advanced/)
- [Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-report-of-the-advanced/)
- [Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/circulating-tumor-cell-biomarker-panel-as-an-individual-level-surrogate-for/)
- [Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-metastatic-and-or/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)

## Researcher university

- [University College Hospital](https://scholariq.org/institutions/university-college-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.